---
title: "Doximity Sinks 24% As AI Push Fails To Ease Growth Fears"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286446269.md"
description: "Doximity shares fell 24% following disappointing Q4 results, prompting analysts to downgrade ratings and lower price targets. KeyBanc Capital Markets downgraded the stock from Overweight to Sector Weight, citing weak fiscal 2027 growth guidance of 3%-5% and challenges in the pharma ad market. Needham maintained a Buy rating but reduced the price target from $55 to $27, noting revenue growth of 5.1% year-on-year but concerns over decelerating growth. Doximity's stock was trading at $17.70 at the time of the report."
datetime: "2026-05-14T16:29:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286446269.md)
  - [en](https://longbridge.com/en/news/286446269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286446269.md)
---

# Doximity Sinks 24% As AI Push Fails To Ease Growth Fears

Shares of **Doximity Inc ( DOCS )** tanked in early trading on Thursday, after the company Wednesday reported downbeat fiscal fourth-quarter results.

Here are the key analyst insights:

-   KeyBanc Capital Markets analyst Scott Schoenhaus downgraded the rating from Overweight to Sector Weight.
-   Needham analyst Bernie McTernan maintained a Buy rating, while reducing the price target from $55 to $27.

**Check out other analyst stock ratings**.

**KeyBanc Capital Markets:** Doximity ( DOCS ) reported its results broadly in-line with expectations. Its fiscal 2027 guidance of 3%-5% growth was disappointing, Schoenhaus said in the downgrade note. The company is unlikely to gain market share with budget managers looking to AI as a lower-cost solution, he added.

**Needham:** Doximity ( DOCS ) reported revenue of $145.4 million and earnings of 26 cents per share. Needham expected $143.5 million and 32 cents per share, respectively.

Total revenue grew 5.1% year-on-year with existing customers continuing to lead growth, he added.

Fears that the company’s growth rate would decelerate towards the broader market growth were realized when management issued fiscal 2027 guidance below street expectations.

"Macro and regulatory uncertainty continue to pressure pharma marketing budgets and as a result of this, DOCS is using FY27 as a time to ramp its investment in AI as the company looks to unlock incremental budget with its new AI Search offering for pharma," McTernan said in the note.

## **Price Action**

Shares of Doximity ( DOCS ) had declined by 24.33% to $17.70 at the time of publication on Thursday.

**Read Also: These Analysts Slash Their Forecasts On Doximity After Q4 Results**

_Image: Shutterstock_

### Related Stocks

- [DOCS.US](https://longbridge.com/en/quote/DOCS.US.md)
- [EKG.US](https://longbridge.com/en/quote/EKG.US.md)
- [LGHT.US](https://longbridge.com/en/quote/LGHT.US.md)
- [HEAL.US](https://longbridge.com/en/quote/HEAL.US.md)

## Related News & Research

- [Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?](https://longbridge.com/en/news/286450300.md)
- [Doximity plunges 24% on weak guidance, analysts slash PTs on increased AI spending](https://longbridge.com/en/news/286405798.md)
- [Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed](https://longbridge.com/en/news/286669018.md)
- [Doximity (NYSE:DOCS) Sets New 52-Week Low After Insider Selling](https://longbridge.com/en/news/286429497.md)
- [Doximity Flags Pharma Ad Market Weakness](https://longbridge.com/en/news/286444124.md)